Browsing by Author "Asgari, Maryam M."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Genome-wide meta-analysis identifies eight new susceptibility loci for cutaneous squamous cell carcinoma
    (Nature Research, 2020-02-10) Sarin, Kavita Y.; Lin, Yuan; Daneshjou, Roxana; Ziyatdinov, Andrey; Thorleifsson, Gudmar; Rubin, Adam; Pardo, Luba M.; Wu, Wenting; Khavari, Paul A.; Uitterlinden, Andre; Nijsten, Tamar; Toland, Amanda E.; Olafsson, Jon H.; Sigurgeirsson, Bardur; Thorisdottir, Kristin; Jorgensen, Eric; Whittemore, Alice S.; Kraft, Peter; Stacey, Simon N.; Stefansson, Kari; Asgari, Maryam M.; Han, Jiali; Epidemiology, School of Public Health
    Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers in the United States. Previous genome-wide association studies (GWAS) have identified 14 single nucleotide polymorphisms (SNPs) associated with cutaneous SCC. Here, we report the largest cutaneous SCC meta-analysis to date, representing six international cohorts and totaling 19,149 SCC cases and 680,049 controls. We discover eight novel loci associated with SCC, confirm all previously associated loci, and perform fine mapping of causal variants. The novel SNPs occur within skin-specific regulatory elements and implicate loci involved in cancer development, immune regulation, and keratinocyte differentiation in SCC susceptibility.
  • Thumbnail Image
    Item
    Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta‐analysis of observational studies
    (Wiley, 2018-03) Tang, Huilin; Fu, Shuangshuang; Zhai, Suodi; Song, Yiqing; Asgari, Maryam M.; Han, Jiali; Epidemiology, School of Public Health
    Purpose Current epidemiologic evidence on the association between antihypertensive drugs and keratinocyte carcinoma (KC) risk is inconsistent. We sought to quantify this association by meta‐analysis of observational studies. Methods We systematically reviewed observational studies published through August 2016 and reported the KC risk (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) associated with antihypertensive drugs, including diuretics, angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta‐adrenergic blocking agents (β‐blockers), and calcium channel blockers (CCBs). Random‐effects meta‐analysis was used to estimate the odds ratio (OR) with 95% confidence interval (CI). Results Ten eligible studies were included. Compared with nonuse, diuretic use was significantly associated with increased risk of both BCC (OR, 1.10; 95% CI, 1.01‐1.20) and SCC (OR, 1.40; 95% CI, 1.19‐1.66). Use of β‐blockers or CCBs was associated with increased risk of BCC (but not SCC); the OR with β‐blockers was 1.09 (95% CI, 1.04‐1.15) and with CCBs was 1.15 (95% CI, 1.09‐1.21). Use of ACE inhibitors or ARBs was associated with decreased risk of both BCC (OR, 0.53; 95% CI, 0.39‐0.71) and SCC (OR, 0.58; 95% CI, 0.42‐0.80) in high‐risk individuals. Conclusions Current evidence indicates that use of diuretics might be associated with increased risk of KC, while ACE inhibitors or ARBs might be associated with decreased risk in high‐risk individuals. β‐blockers or CCBs might be positively associated with BCC risk. Further postmarketing surveillance studies and investigations to clarify the possible underlying mechanisms are warranted.